Merck & Company Inc (MRK)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 30,592,000 | 27,923,000 | 23,093,000 | 18,184,000 | 18,980,000 |
Revenue | US$ in thousands | 60,115,000 | 59,283,000 | 48,704,000 | 41,518,000 | 39,121,000 |
Gross profit margin | 50.89% | 47.10% | 47.41% | 43.80% | 48.52% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $30,592,000K ÷ $60,115,000K
= 50.89%
Merck & Co Inc's gross profit margin has shown a generally increasing trend over the past five years, peaking at 73.17% in 2023. This indicates that the company is effectively managing its production costs and pricing strategies to generate a higher proportion of revenue as gross profit. The consistently high gross profit margins reflect Merck's ability to maintain a competitive advantage and effectively control its cost of goods sold. Overall, the increasing trend in gross profit margin suggests efficiency in operations and strong pricing power within the pharmaceutical industry.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Merck & Company Inc
MRK
50.89%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
16.39%
Alkermes Plc
ALKS
39.97%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-6.84%
Biomarin Pharmaceutical Inc
BMRN
78.31%
Bristol-Myers Squibb Company
BMY
37.71%
Catalent Inc
CTLT
21.75%
Catalyst Pharmaceuticals Inc
CPRX
45.19%